Could an immunotherapy drug keep early lung cancer from returning?
NCT ID NCT07388524
First seen Jun 27, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase III trial is testing whether the immunotherapy drug atezolizumab, given after surgery, can prevent stage I non-small cell lung cancer from returning. About 336 patients who have had their tumor completely removed will be randomly assigned to receive either atezolizumab (with or without hyaluronidase to aid absorption) or standard observation. The goal is to see if the drug improves disease-free survival compared to just watching and waiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Atezolizumab (an immunotherapy drug that helps the immune system attack cancer cells)
What this could lead to
If successful, this could offer a way to reduce the risk of lung cancer returning after surgery, potentially improving long-term outcomes for early-stage patients.
What could go wrong
This is an early-stage cancer trial, and immunotherapy can cause side effects like inflammation in healthy organs. The benefit over standard observation is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG NON-SMALL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alliance for Clinical Trials in Oncology
RECRUITINGChicago, Illinois, 60606, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Mercy Hospital
RECRUITINGCedar Rapids, Iowa, 52403, United States
Contact
Contact Phone: •••-•••-••••
-
Oncology Associates at Mercy Medical Center
RECRUITINGCedar Rapids, Iowa, 52403, United States
Contact
Contact Phone: •••-•••-••••